SCHEMBL5379166

SCHEMBL5379166

CC(C)(CC(O)(C=O)C1CCCC1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
CHRM2 P08172 8/20 0.41
CHRM1 P11229 8/20 0.41
CYP2D6 P10635 4/20 0.41
KCNH2 Q12809 4/20 0.41
ALDH1A1 P00352 1/20 0.40
CHRM3 P20309 7/20 0.40
POLB P06746 1/20 0.39
CHRM4 P08173 4/20 0.39
CHRM5 P08912 2/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
HRH1 P35367 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5388597 0.76 NR3C1 (0.45) KEAP1NFE2L2CHRM2CHRM1CYP2D6
SCHEMBL5384465 0.76 KEAP1 (0.45) KEAP1NFE2L2CHRM2CHRM1CYP2D6
SCHEMBL28061975 0.74 KEAP1 (0.42) KEAP1NFE2L2CHRM2CHRM1CYP2D6
SCHEMBL27769779 0.73 POLB (0.47) KEAP1NFE2L2CHRM2CHRM1CYP2D6
SCHEMBL27698824 0.73 KEAP1 (0.47) KEAP1NFE2L2CHRM2CHRM1CYP2D6
SCHEMBL5381131 0.73 TAAR1 (0.44) ALDH1A1POLBCYP3A4MAPT
SCHEMBL22257216 0.73 KEAP1 (0.56) KEAP1NFE2L2CHRM2CHRM1CYP2D6
SCHEMBL17771882 0.71 KEAP1 (0.58) KEAP1NFE2L2CHRM2CHRM1CYP2D6
SCHEMBL5373643 0.71 CHRM2 (0.47) KEAP1NFE2L2CHRM2CHRM1CYP2D6
SCHEMBL28062010 0.71 KEAP1 (0.54) KEAP1NFE2L2CHRM2CHRM1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238707-B2 Substituted pentanols, a process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2007-07-03 US disclosed
CN-1863775-A 1- (quinoline-amino) -and 1- (isoquinoline-amino) -substituted pentanols, process for their preparation and their use as anti-inflammatory agents SCHERING AG (DE) 2006-11-15 CN disclosed
EP-1673344-A1 1-(QUINOLINE AMINO) AND 1-(ISOQUINOLINE AMINO)-SUBSTITUTED PENTAN-2-OLS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORIES Schering Aktiengesellschaft (DE) 2006-06-28 EP disclosed
US-20050143415-A1 Substituted pentanols, a process for their production and their use as anti-inflammatory agents SCHERING AG (DE) 2005-06-30 US disclosed
WO-2005035502-A1 1-(QUINOLINE AMINO) AND 1-(ISOQUINOLINE AMINO)-SUBSTITUTED PENTAN-2-OLS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORIES SCHERING AKTIENGESELLSCHAFT (DE) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143415-A1 Substituted pentanols, a process for their production and their use as anti-inflammatory agents PTGES, TNF, PTGES2 KEAP1 2512/4885NFE2L2 252/4885CHRM2 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.